Secondary Cytoreduction Followed by Chemotherapy Versus Chemotherapy Alone in Relapsed Ovarian Cancer After PARPi Maintenance Treatment: a Multicentre, Open-label, Randomised, Phase 3 Trial

This study is for women with ovarian cancer (including fallopian tube and peritoneal cancers) that has come back after initial treatment including PARP inhibitor maintenance therapy. It compares doing a second surgery to remove as much tumor as possible (cytoreduction) followed by chemotherapy, versus chemotherapy alone. **You may be eligible if...** - You have first- or second-line recurrent ovarian, peritoneal, or fallopian tube cancer - Your cancer came back more than 6 months after completing platinum-based chemotherapy - You received PARP inhibitor maintenance therapy for more than 6 months before relapse - Your initial surgery achieved complete tumor removal (R0) - Your cancer has recurred in 5 or fewer isolated spots, with minimal fluid in the abdomen - Your performance status is ECOG 0 or 1 **You may NOT be eligible if...** - Your cancer came back within 6 months of chemotherapy - You have widespread or numerous recurrence sites - You have significant excess abdominal fluid Talk to your doctor to see if this trial is right for you.